RIN Institute
RIN Institute is a bio-venture established at the National Cancer Center Japan, focusing on the research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company aims to contribute to the global cancer medical field by developing innovative antibody-based therapies and diagnostics, leveraging Japan's craftsmanship and scientific expertise.
Industries
Nr. of Employees
medium (51-250)
RIN Institute
1-13-10-2F Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan
Patents
Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method
US-11524074-B2
View DetailsAntibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
US-11377504-B2
View DetailsCancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method
US-10471146-B2
View Details
Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method
US-11524074-B2
View DetailsAntibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
US-11377504-B2
View DetailsCancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method
US-10471146-B2
View DetailsProducts
Humanized monoclonal antibody targeting a colorectal cancer-specific membrane protein (TMEM180)
A humanized monoclonal antibody directed against a membrane protein highly expressed in colorectal cancer with demonstrated ADCC/ADCP activity and antitumor efficacy in PDX models; advanced to Phase I clinical trial.
Antibody-drug conjugate targeting insoluble fibrin in tumor stroma
An ADC that binds insoluble fibrin in the tumor stroma, uses a plasmin-cleavable linker to release MMAE locally, and is designed to overcome limited macromolecule penetration in human solid tumors.
Thrombolytic fusion protein using antibody Fab fused to mutated urokinase
A fusion protein combining an antibody Fab that binds insoluble fibrin with a mutated urokinase designed to selectively deliver thrombolytic activity to thrombi while reducing systemic bleeding risk.
Additional oncology antibody pipelines (e.g., TMEM132A-targeting antibody, bispecific anti-target/CD3, tissue factor ADC)
Multiple follow-on antibody programs including ADCs and bispecific formats targeting additional cancer-specific membrane proteins and tissue factor.
Humanized monoclonal antibody targeting a colorectal cancer-specific membrane protein (TMEM180)
A humanized monoclonal antibody directed against a membrane protein highly expressed in colorectal cancer with demonstrated ADCC/ADCP activity and antitumor efficacy in PDX models; advanced to Phase I clinical trial.
Antibody-drug conjugate targeting insoluble fibrin in tumor stroma
An ADC that binds insoluble fibrin in the tumor stroma, uses a plasmin-cleavable linker to release MMAE locally, and is designed to overcome limited macromolecule penetration in human solid tumors.
Thrombolytic fusion protein using antibody Fab fused to mutated urokinase
A fusion protein combining an antibody Fab that binds insoluble fibrin with a mutated urokinase designed to selectively deliver thrombolytic activity to thrombi while reducing systemic bleeding risk.
Additional oncology antibody pipelines (e.g., TMEM132A-targeting antibody, bispecific anti-target/CD3, tissue factor ADC)
Multiple follow-on antibody programs including ADCs and bispecific formats targeting additional cancer-specific membrane proteins and tissue factor.
Services
End-to-end preclinical R&D including target identification, antibody generation and characterization, efficacy studies in PDX models, and GLP toxicology to support clinical entry.
GMP production development and preparation of clinical supply for antibody therapeutics.
End-to-end preclinical R&D including target identification, antibody generation and characterization, efficacy studies in PDX models, and GLP toxicology to support clinical entry.
GMP production development and preparation of clinical supply for antibody therapeutics.
Expertise Areas
- Therapeutic monoclonal antibody development
- Antibody-drug conjugate (ADC) development
- Cancer stromal targeting strategies
- Preclinical in vivo models (PDX)
Key Technologies
- Monoclonal antibody generation and humanization
- Antibody-drug conjugation (MMAE payload)
- Protease-cleavable peptide linkers (plasmin-activated)
- Patient-derived xenograft (PDX) models
News & Updates
In 2016, the company was recognized as a venture originating from the National Cancer Center, and its research on antibody drugs for cancer has been highly cited.
Dr. Matsumura, the company's Director of Research and Development, was awarded the Thomson Reuters Citation Honor in 2016 for his work on the EPR effect and cancer stromal targeting therapy.
The latest issue of Nature features articles on Dr. Matsumura and the company's pipeline, including anti-TMEM180 and anti-insoluble fibrin antibody.
Recognized for his pioneering work on the EPR effect and cancer stromal targeting therapy, Dr. Matsumura's research has been highly cited globally.
In 2016, the company was recognized as a venture originating from the National Cancer Center, and its research on antibody drugs for cancer has been highly cited.
Dr. Matsumura, the company's Director of Research and Development, was awarded the Thomson Reuters Citation Honor in 2016 for his work on the EPR effect and cancer stromal targeting therapy.
The latest issue of Nature features articles on Dr. Matsumura and the company's pipeline, including anti-TMEM180 and anti-insoluble fibrin antibody.
Recognized for his pioneering work on the EPR effect and cancer stromal targeting therapy, Dr. Matsumura's research has been highly cited globally.